Tert-butyl-[4-(2-cyclopropylethynoxy)-3-ethyl-6-fluoroquinolin-2-yl]oxy-dimethylsilane | 777096-90-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 喹啉及其衍生物
• 英文名称: Tert-butyl-[4-(2-cyclopropylethynoxy)-3-ethyl-6-fluoroquinolin-2-yl]oxy-dimethylsilane
• CAS: 777096-90-9
• 化学式: C₂₂H₂₈FNO₂Si
• 分子量: 385.554
• InChiKey: ZLDWCPGWCOPGEG-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  6.07
• 重原子数：
  27
• 可旋转键数：
  6
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  31.4
• 氢给体数：
  0
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  Tert-butyl-[4-(2-cyclopropylethynoxy)-3-ethyl-6-fluoroquinolin-2-yl]oxy-dimethylsilane 在 acidic resin AG 50W-X₄ 作用下， 以 四氢呋喃 为溶剂， 以18 mg的产率得到4-[(2-Cyclopropylethynyl)oxy]-3-ethyl-6-fluoro-2(1H)-quinolinone
  参考文献：
  名称：

  Design of Non-nucleoside Inhibitors of HIV-1 Reverse Transcriptase with Improved Drug Resistance Properties. 2.

  摘要：

  HIV-1 nonnucleoside reverse transcriptase inhibitors (NNRTIs) are part of the combination therapy currently used to treat HIV infection. The features of a new NNRTI drug for HIV treatment must include selective potent activity against both wild-type virus as well as against mutant virus that have been selected by use of current antiretroviral treatment regimens. Based on analogy with known HIV-1 NNRTI inhibitors and modeling studies utilizing the X-ray crystal structure of inhibitors bound in the HIV-1 RT, a series of substituted 2-quinolones was synthesized and evaluated as HIV-1 inhibitors.

  DOI：

  10.1021/jm040072r
• 作为产物：
  描述：

  ethyl 2-(chlorocarbonyl)butanoate 在 甲烷磺酸 、 phosphorus pentoxide 、 lithium 、 sodium hydride 、 三乙胺 作用下， 以 乙醚 、 二氯甲烷 、 N,N-二甲基甲酰胺 为溶剂， 反应 2.5h， 生成 Tert-butyl-[4-(2-cyclopropylethynoxy)-3-ethyl-6-fluoroquinolin-2-yl]oxy-dimethylsilane
  参考文献：
  名称：

  Design of Non-nucleoside Inhibitors of HIV-1 Reverse Transcriptase with Improved Drug Resistance Properties. 2.

  摘要：

  HIV-1 nonnucleoside reverse transcriptase inhibitors (NNRTIs) are part of the combination therapy currently used to treat HIV infection. The features of a new NNRTI drug for HIV treatment must include selective potent activity against both wild-type virus as well as against mutant virus that have been selected by use of current antiretroviral treatment regimens. Based on analogy with known HIV-1 NNRTI inhibitors and modeling studies utilizing the X-ray crystal structure of inhibitors bound in the HIV-1 RT, a series of substituted 2-quinolones was synthesized and evaluated as HIV-1 inhibitors.

  DOI：

  10.1021/jm040072r

文献信息

• Design of Non-nucleoside Inhibitors of HIV-1 Reverse Transcriptase with Improved Drug Resistance Properties. 2.
  作者：George A. Freeman、C. Webster Andrews、Andrew L. Hopkins、Gina S. Lowell、Lee T. Schaller、Jill R. Cowan、Stephen S. Gonzales、George W. Koszalka、Richard J. Hazen、Lawrence R. Boone、Rob G. Ferris、Katrina L. Creech、Grace B. Roberts、Steven A. Short、Kurt Weaver、David J. Reynolds、John Milton、Jingshan Ren、David I. Stuart、David K. Stammers、Joseph H. Chan

  DOI：10.1021/jm040072r

  日期：2004.11.1

  HIV-1 nonnucleoside reverse transcriptase inhibitors (NNRTIs) are part of the combination therapy currently used to treat HIV infection. The features of a new NNRTI drug for HIV treatment must include selective potent activity against both wild-type virus as well as against mutant virus that have been selected by use of current antiretroviral treatment regimens. Based on analogy with known HIV-1 NNRTI inhibitors and modeling studies utilizing the X-ray crystal structure of inhibitors bound in the HIV-1 RT, a series of substituted 2-quinolones was synthesized and evaluated as HIV-1 inhibitors.